{"id":382,"date":"2020-07-18T11:12:05","date_gmt":"2020-07-18T11:12:05","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=382"},"modified":"2020-07-18T11:12:05","modified_gmt":"2020-07-18T11:12:05","slug":"17-july-2020-dexamethasone-resulted-in-lower-28-day-mortality","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/17-july-2020-dexamethasone-resulted-in-lower-28-day-mortality\/","title":{"rendered":"(17 July 2020) Dexamethasone- resulted in lower 28-day mortality"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"m-article-header__title f-h18\"><span class=\"title_default\">Dexamethasone in Hospitalized Patients with Covid-19 \u2014 Preliminary Report<\/span><\/p>\n<p class=\"\">https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2021436?query=featured_coronavirus<\/p>\n<p class=\"f-body\">In this controlled, open-label trial (RECOVERY ClinicalTrials.gov number,&nbsp;<a class=\"ext-link\" href=\"http:\/\/clinicaltrials.gov\/show\/NCT04381936\" target=\"_blank\" rel=\"noopener noreferrer\">NCT04381936<\/a>)comparing a range of possible treatments in patients who were hospitalized with Covid-19,&nbsp; patients were randomly assigned to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Preliminary results are reported here. A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P&lt;0.001). In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.91 to 1.55). In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dexamethasone in Hospitalized Patients with Covid-19 \u2014 Preliminary Report https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2021436?query=featured_coronavirus In this controlled, open-label trial (RECOVERY ClinicalTrials.gov number,&nbsp;NCT04381936)comparing a range of possible treatments in patients who were hospitalized with Covid-19,&nbsp; patients were randomly assigned to receive oral or intravenous dexamethasone&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/17-july-2020-dexamethasone-resulted-in-lower-28-day-mortality\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(17 July 2020) Dexamethasone- resulted in lower 28-day mortality&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,8],"tags":[68],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/382"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=382"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/382\/revisions"}],"predecessor-version":[{"id":383,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/382\/revisions\/383"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}